Nanosonics Ltd
ASX:NAN

Watchlist Manager
Nanosonics Ltd Logo
Nanosonics Ltd
ASX:NAN
Watchlist
Price: 3.01 AUD -0.33% Market Closed
Market Cap: 913.7m AUD
Have any thoughts about
Nanosonics Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one NAN stock under the Base Case scenario is 3.25 AUD. Compared to the current market price of 3.01 AUD, Nanosonics Ltd is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NAN Relative Value
Base Case
3.25 AUD
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.4
P/S
P/S
Price to Sales
5.4
vs History
85
vs Industry
23
Median 3Y
8.6
Median 5Y
10.9
Industry
2.3
Forward
4.8
More Details
70.3
P/E
P/E
Price to Earnings
70.3
vs History
76
vs Industry
7
Median 3Y
86.2
Median 5Y
152.7
Industry
23
Forward
70.7
More Details
40
P/OCF
P/OCF
Price to OCF
40
vs History
85
vs Industry
9
Median 3Y
62
Median 5Y
105.8
Industry
14.3
More Details
52.8
P/FCFE
P/FCFE
Price to FCFE
52.8
vs History
76
vs Industry
11
Median 3Y
68.6
Median 5Y
106.4
Industry
20
More Details
5
P/B
P/B
Price to Book Value
5
vs History
85
vs Industry
15
Median 3Y
7.8
Median 5Y
10.1
Industry
2.2
More Details
4.6
EV/S
EV/S
Enterprise Value to Sales
4.6
vs History
85
vs Industry
23
Median 3Y
8
Median 5Y
10.2
Industry
2.4
Forward
4.2
More Details
6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6
vs History
85
vs Industry
35
Median 3Y
10.3
Median 5Y
13.2
Industry
5
More Details
92
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
92
vs History
71
vs Industry
2
Median 3Y
99
Median 5Y
146.8
Industry
12.9
Forward
41
More Details
92
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
92
vs History
71
vs Industry
3
Median 3Y
99
Median 5Y
146.8
Industry
17.4
Forward
68
More Details
34.6
EV/OCF
EV/OCF
Enterprise Value to OCF
34.6
vs History
85
vs Industry
11
Median 3Y
57.5
Median 5Y
100.1
Industry
14
More Details
38.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
38.9
vs History
76
vs Industry
12
Median 3Y
53.8
Median 5Y
93.6
Industry
18.2
More Details
8.1
EV/IC
EV/IC
Enterprise Value to IC
8.1
vs History
85
vs Industry
10
Median 3Y
12.2
Median 5Y
15.8
Industry
1.9
More Details

Multiples Across Competitors

NAN Competitors Multiples
Nanosonics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Nanosonics Ltd
ASX:NAN
912m AUD 5.4 70.3 92 92
JP
Hoya Corp
TSE:7741
7T JPY 8.6 35.9 23.7 28.5
CH
Alcon AG
SIX:ALC
38.2B CHF 4.3 36.2 17.8 34.4
DK
Coloplast A/S
CSE:COLO B
177.1B DKK 6.6 35.1 22.6 26.6
US
Align Technology Inc
NASDAQ:ALGN
16.3B USD 4.1 36.8 18.6 22.4
KR
HLB Inc
KOSDAQ:028300
10.3T KRW 198.6 -55.5 -85.5 -80.6
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
51B CNY 11.5 27.6 23.9 23.9
US
Lantheus Holdings Inc
NASDAQ:LNTH
6.7B USD 4.5 15.8 10.9 12.4
CA
Bausch + Lomb Corp
NYSE:BLCO
6.3B USD 1.3 -17.1 16.6 55.6
UK
ConvaTec Group PLC
LSE:CTEC
4.6B GBP 2.6 37.1 264.5 462
US
Merit Medical Systems Inc
NASDAQ:MMSI
5.6B USD 4.2 46.5 23.2 38.1
P/E Multiple
Earnings Growth PEG
AU
Nanosonics Ltd
ASX:NAN
Average P/E: 37.9
70.3
29%
2.4
JP
Hoya Corp
TSE:7741
35.9
15%
2.4
CH
Alcon AG
SIX:ALC
36.2
27%
1.3
DK
Coloplast A/S
CSE:COLO B
35.1
15%
2.3
US
Align Technology Inc
NASDAQ:ALGN
36.8
26%
1.4
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -55.5 N/A N/A
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
27.6
24%
1.1
US
Lantheus Holdings Inc
NASDAQ:LNTH
15.8
19%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -17.1 N/A N/A
UK
ConvaTec Group PLC
LSE:CTEC
37.1
46%
0.8
US
Merit Medical Systems Inc
NASDAQ:MMSI
46.5
37%
1.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Nanosonics Ltd
ASX:NAN
Average EV/EBITDA: 51.4
92
68%
1.4
JP
Hoya Corp
TSE:7741
23.7
15%
1.6
CH
Alcon AG
SIX:ALC
17.8
10%
1.8
DK
Coloplast A/S
CSE:COLO B
22.6
11%
2.1
US
Align Technology Inc
NASDAQ:ALGN
18.6
15%
1.2
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -85.5 N/A N/A
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
23.9
27%
0.9
US
Lantheus Holdings Inc
NASDAQ:LNTH
10.9
11%
1
CA
Bausch + Lomb Corp
NYSE:BLCO
16.6
22%
0.8
UK
ConvaTec Group PLC
LSE:CTEC
264.5
12%
22
US
Merit Medical Systems Inc
NASDAQ:MMSI
23.2
22%
1.1

See Also

Summary
NAN intrinsic value, competitors valuation, and company profile.
DCF Valuation
NAN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NAN stock valuation using valuation multiples.
Wall Street Estimates
NAN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NAN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 215,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.